SuperworthBullFrog AI BFRG
- Market cap
- $9.2M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
BullFrog AI's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $65K | $0 | n/a | n/a | n/a | n/a | n/a | $33.3K | $83.4K | $0 | n/a | $215.4K+548% | |
| Cost of revenue | $5.2K | $0 | n/a | n/a | n/a | n/a | n/a | $26.7K | $68K | $0 | n/a | $108.5K+306% |
| Gross profit | $59.8K | $0 | n/a | n/a | n/a | n/a | n/a | $6.5K | $15.4K | $0 | n/a | $106.9K+1539% |
| R&D | $380K+864% | $409K+154% | $552.1K+49% | $513.7K+88% | $566.6K+49% | $590.9K+45% | $576.3K+4% | $480.3K−7% | $346K−39% | $397.2K−33% | $434.8K−25% | $339.5K−29% |
| SG&A | $983.9K+64% | $926.8K+115% | $1.4M+72% | $1.2M−8% | $1.3M+27% | $1.2M+27% | $1.5M+5% | $995.9K−15% | $1.2M−1% | $1.1M−7% | $1.2M−20% | $1.2M+19% |
| −$1.3M+104% | −$1.3M+129% | −$2M+65% | −$1.7M+9% | −$1.8M+40% | −$1.8M+32% | −$2.1M+5% | −$1.5M−13% | −$1.6M−14% | −$1.5M−15% | −$1.6M−22% | −$1.4M−3% | |
| Interest expense | $5.8K−95% | $2.2K−98% | $3.3K−95% | $7.9K−27% | $5K−14% | $2K−9% | $1K−69% | $2.4K−69% | $1.5K−69% | $622−69% | $982−3% | $2.4K−3% |
| Net income | −$1.3M+64% | −$1.3M+87% | −$1.9M+44% | −$1.6M+9% | −$1.8M+41% | −$1.7M+32% | −$2M+6% | −$1.4M−10% | −$1.6M−12% | −$1.5M−14% | −$1.6M−21% | −$1.4M−5% |
| −$0.21+31% | −$0.18−47% | −$0.26−4% | −$0.20−17% | −$0.22+5% | −$0.19+6% | −$0.21−19% | −$0.15−25% | −$0.15−32% | −$0.13−32% | −$0.12−43% | −$0.07−53% | |
| 6.1M+28% | 7.2M+250% | 7.4M+53% | 8.1M+34% | 8.1M+33% | 9.3M+30% | 9.7M+31% | 9.7M+20% | 10.4M+28% | 11.6M+24% | 12.9M+34% | 18.8M+94% |
EPS, diluted: 5 periods, Q1 FY22 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY22: share-days: the 6-month average less the second quarter's. 4 periods, Q4 FY22 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest BullFrog AI's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BFRGBullFrog AI | $9.2M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on BullFrog AI
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .